Hepatitis C and Liver Transplantation: Enhancing Outcomes and Should Patients Be Retransplanted, Clinics in Liver Disease, vol.12, issue.3, pp.637-659, 2008. ,
DOI : 10.1016/j.cld.2008.03.010
Consensus proposals for a unified system of nomenclature of hepatitis C virus genotypes, Hepatology, vol.17, issue.4, pp.962-973, 2005. ,
DOI : 10.1002/hep.20819
URL : https://hal.archives-ouvertes.fr/hal-00313678
Hepatitis C Virus Continuously Escapes From Neutralizing Antibody and T-Cell Responses During Chronic Infection In Vivo, Gastroenterology, vol.132, issue.2, pp.667-678, 2007. ,
DOI : 10.1053/j.gastro.2006.12.008
Telaprevir for Previously Treated Chronic HCV Infection, New England Journal of Medicine, vol.362, issue.14, pp.1292-1303, 2010. ,
DOI : 10.1056/NEJMoa0908014
Antiviral strategies in hepatitis C virus infection, Journal of Hepatology, vol.56, pp.88-100, 2012. ,
DOI : 10.1016/S0168-8278(12)60010-5
New direct-acting antiviral agents for the treatment of hepatitis C virus infection and perspectives, Gut, vol.61, issue.Suppl 1, pp.36-46, 2012. ,
DOI : 10.1136/gutjnl-2012-302144
Sustained E2 antibody response correlates with reduced peak viremia after hepatitis C virus infection in the chimpanzee, Hepatology, vol.74, issue.6, pp.1429-1436, 2005. ,
DOI : 10.1002/hep.20934
Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge, Nature Medicine, vol.78, issue.1, pp.25-27, 2008. ,
DOI : 10.1016/j.virol.2006.05.015
Human Monoclonal Antibody HCV1 Effectively Prevents and Treats HCV Infection in Chimpanzees, PLoS Pathogens, vol.8, issue.8, p.1002895, 2012. ,
DOI : 10.1371/journal.ppat.1002895.t004
Human Monoclonal Antibody MBL-HCV1 Delays HCV Viral Rebound Following Liver Transplantation: A Randomized Controlled Study, American Journal of Transplantation, vol.132, issue.5 Pt 1, 2013. ,
DOI : 10.1111/ajt.12083
Selection Pressure From Neutralizing Antibodies Drives Sequence Evolution During Acute Infection With Hepatitis C Virus, Gastroenterology, vol.136, issue.7, pp.2377-2386, 2009. ,
DOI : 10.1053/j.gastro.2009.02.080
Rapid induction of virus-neutralizing antibodies and viral clearance in a single-source outbreak of hepatitis C, Proceedings of the National Academy of Sciences, vol.104, issue.14, pp.6025-6030, 2007. ,
DOI : 10.1073/pnas.0607026104
URL : https://hal.archives-ouvertes.fr/inserm-00395910
Association of anti-E1E2 antibodies with spontaneous recovery or sustained viral response to therapy in patients infected with hepatitis C virus, Hepatology, vol.461, issue.5, pp.1531-1542, 2010. ,
DOI : 10.1002/hep.23862
Neutralizing Antibody-Resistant Hepatitis C Virus Cell-to-Cell Transmission, Journal of Virology, vol.85, issue.1, pp.596-605, 2011. ,
DOI : 10.1128/JVI.01592-10
Hepatitis C virus cell-cell transmission in hepatoma cells in the presence of neutralizing antibodies, Hepatology, vol.7, issue.1, pp.17-24, 2008. ,
DOI : 10.1002/hep.21959
CD81 is dispensable for hepatitis C virus cell-to-cell transmission in hepatoma cells, Journal of General Virology, vol.90, issue.1, pp.48-58, 2009. ,
DOI : 10.1099/vir.0.006700-0
Naturally occurring antibodies devoid of light chains, Nature, vol.363, issue.6428, pp.446-448, 1993. ,
DOI : 10.1038/363446a0
Single-domain antibodies recognize selectively small oligomeric forms of amyloid ??, prevent A??-induced neurotoxicity and inhibit fibril formation, Molecular Immunology, vol.46, issue.4, pp.695-704, 2009. ,
DOI : 10.1016/j.molimm.2008.09.008
Properties, production, and applications of camelid single-domain antibody fragments, Applied Microbiology and Biotechnology, vol.77, issue.1, pp.13-22, 2007. ,
DOI : 10.1007/s00253-007-1142-2
Nanobodies??: New ammunition to battle viruses, Antiviral Research, vol.92, issue.3, pp.389-407, 2011. ,
DOI : 10.1016/j.antiviral.2011.09.002
In vitro antiviral activity of single domain antibody fragments against poliovirus, Antiviral Research, vol.87, issue.2, pp.257-264, 2010. ,
DOI : 10.1016/j.antiviral.2010.05.012
Early infection events highlight the limited transmissibility of hepatitis C virus in vitro, Journal of Hepatology, vol.58, issue.6, 2013. ,
DOI : 10.1016/j.jhep.2013.01.019
Hepatitis C Patient-Derived Glycoproteins Exhibit Marked Differences in Susceptibility to Serum Neutralizing Antibodies: Genetic Subtype Defines Antigenic but Not Neutralization Serotype, Journal of Virology, vol.85, issue.9, pp.4246-4257, 2011. ,
DOI : 10.1128/JVI.01332-10
Human combinatorial libraries yield rare antibodies that broadly neutralize hepatitis C virus, Proceedings of the National Academy of Sciences, vol.104, issue.41, pp.16269-16274, 2007. ,
DOI : 10.1073/pnas.0705522104
Comparison of llama VH sequences from conventional and heavy chain antibodies, Molecular Immunology, vol.34, issue.16-17, pp.1121-1131, 1997. ,
DOI : 10.1016/S0161-5890(97)00146-6
Camel heavy-chain antibodies: diverse germline VHH and specific mechanisms enlarge the antigen-binding repertoire, The EMBO Journal, vol.376, issue.5, pp.921-930, 2000. ,
DOI : 10.1093/emboj/19.5.921
Structural Insights into the Evolution of an Antibody Combining Site, Science, vol.276, issue.5319, pp.1665-1669, 1997. ,
DOI : 10.1126/science.276.5319.1665
The role of neutralizing antibodies in hepatitis C virus infection, Journal of General Virology, vol.93, issue.1, pp.1-19, 2012. ,
DOI : 10.1099/vir.0.035956-0
The green tea polyphenol, epigallocatechin-3-gallate, inhibits hepatitis C virus entry, Hepatology, vol.76, issue.6, pp.1947-1955, 2011. ,
DOI : 10.1002/hep.24610
A Novel Small Molecule Inhibitor of Hepatitis C Virus Entry, PLoS Pathogens, vol.62, issue.9, p.1001086, 2010. ,
DOI : 10.1371/journal.ppat.1001086.t005
Efficient method for production of high yields of Fab fragments in Drosophila S2 cells, Protein Engineering Design and Selection, vol.23, issue.4, pp.169-174, 2010. ,
DOI : 10.1093/protein/gzp088
URL : https://hal.archives-ouvertes.fr/pasteur-00460809
High-level secretion of recombinant monomeric murine and human single-chain Fv antibodies from Drosophila S2 cells, Protein Engineering Design and Selection, vol.25, issue.2, pp.59-66, 2012. ,
DOI : 10.1093/protein/gzr058
Hepatitis C virus kinetics during and immediately after liver transplantation, Hepatology, vol.68, issue.3, pp.680-687, 2002. ,
DOI : 10.1053/jhep.2002.31773
Effect of telaprevir on the pharmacokinetics of cyclosporine and tacrolimus, Hepatology, vol.37, issue.10 Suppl 2, pp.20-27, 2011. ,
DOI : 10.1002/hep.24443
The Disulfide Bonds in Glycoprotein E2 of Hepatitis C Virus Reveal the Tertiary Organization of the Molecule, PLoS Pathogens, vol.14, issue.2, p.1000762, 2010. ,
DOI : 10.1371/journal.ppat.1000762.s005
URL : https://hal.archives-ouvertes.fr/pasteur-00460826
Structural basis of hepatitis C virus neutralization by broadly neutralizing antibody HCV1, Proceedings of the National Academy of Sciences, vol.109, issue.24, pp.9499-9504, 2012. ,
DOI : 10.1073/pnas.1202924109
Characterization of the hepatitis C virus E2 epitope defined by the broadly neutralizing monoclonal antibody AP33, Hepatology, vol.399, issue.3, pp.592-601, 2006. ,
DOI : 10.1002/hep.21088
Mapping a Region of Hepatitis C Virus E2 That Is Responsible for Escape from Neutralizing Antibodies and a Core CD81-Binding Region That Does Not Tolerate Neutralization Escape Mutations, Journal of Virology, vol.85, issue.20, pp.10451-10463, 2011. ,
DOI : 10.1128/JVI.05259-11
URL : https://hal.archives-ouvertes.fr/pasteur-00630502
The Hepatitis C Virus Glycan Shield and Evasion of the Humoral Immune Response, Viruses, vol.3, issue.12, pp.1909-1932, 2011. ,
DOI : 10.3390/v3101909
Avoiding the void: cell-to-cell spread of human viruses, Nature Reviews Microbiology, vol.73, issue.11, pp.815-826, 2008. ,
DOI : 10.1038/nrmicro1972